新科学想法 › 学术文库 › 学术文献 › 浏览文献

Glycine transporter-1: a new potential therapeutic target for schizophrenia

jordanarise 添加于 2011-10-11 12:33 | 851 次阅读 | 0 个评论

作者
Hashimoto K
摘要
The hypofunction hypothesis of glutamatergic neurotransmission via N-methyl-D-aspartate (NMDA) receptors in the pathophysiology of schizophrenia suggests that increasing NMDA receptor function via pharmacological manipulation could provide a new therapeutic strategy for schizophrenia. The glycine modulatory site on NMDA receptor complex is the one of the most attractive therapeutic targets for schizophrenia. One means of enhancing NMDA receptor neurotransmission is to increase the availability of the obligatory co-agonist glycine at modulatory site on the NMDA receptors through the inhibition of glycine transporter-1 (GlyT-1) on glial cells. Some clinical studies have demonstrated that the GlyT-1 inhibitor sarcosine (N-methylglycine) shows antipsychotic activity in patients with schizophrenia. Currently, a number of pharmaceutical companies have been developing novel and selective GlyT-1 inhibitors for the treatment of schizophrenia. A recent double blind phase II study demonstrated that the novel GlyT-1 inhibitor RG1678 has a robust and clinically meaningful effect in patients with schizophrenia. In this article, the author reviews the recent findings on the GlyT-1 as a potential therapeutic target of schizophrenia.
详细资料
- 文献种类: Journal Article
- 期刊名称: Current Pharmaceutical Design
- 期刊缩写: Curr Pharm Des
- 期卷页: 2011年第17卷第2期 112-120页
- 地址: Division of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, 1-8-1 Inohana, Chiba 260-8670, Japan. hashimoto@faculty.chiba-u.jp
- ISBN: 1381-6128
- 备注:PMID:21355838
学科领域生物医药 » 临床医学
相关链接 URL
jordanarise 的文献笔记订阅